NasdaqGS:MDGLBiotechs
Is Stronger Rezdiffra Momentum and New Patents Altering The Investment Case For Madrigal Pharmaceuticals (MDGL)?
Madrigal Pharmaceuticals, Inc. has reported past second-quarter 2026 results showing a net loss of US$57.94 million and basic and diluted loss per share of US$1.99, widening from US$42.28 million and US$1.50 per share a year earlier, despite beating analyst expectations on earnings and revenue.
Alongside this, the company highlighted growing Rezdiffra sales in MASH, new patents extending protection for resmetirom, and the start of Phase 1 testing for its oral GLP-1 candidate MGL-2086 aimed...